These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 26975040)
1. Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features. Espinosa I; D'Angelo E; Palacios J; Prat J Am J Surg Pathol; 2016 Jul; 40(7):972-81. PubMed ID: 26975040 [TBL] [Abstract][Full Text] [Related]
2. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study. Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180 [TBL] [Abstract][Full Text] [Related]
3. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767 [TBL] [Abstract][Full Text] [Related]
5. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors. Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621 [TBL] [Abstract][Full Text] [Related]
6. Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis. Espinosa I; Lee CH; D'Angelo E; Palacios J; Prat J Am J Surg Pathol; 2017 Aug; 41(8):1121-1128. PubMed ID: 28498284 [TBL] [Abstract][Full Text] [Related]
7. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778 [TBL] [Abstract][Full Text] [Related]
8. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675 [TBL] [Abstract][Full Text] [Related]
9. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Bartosch C; Manuel Lopes J; Oliva E Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268 [TBL] [Abstract][Full Text] [Related]
10. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. Köbel M; Meng B; Hoang LN; Almadani N; Li X; Soslow RA; Gilks CB; Lee CH Am J Surg Pathol; 2016 Feb; 40(2):166-180. PubMed ID: 26492180 [TBL] [Abstract][Full Text] [Related]
11. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma. Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301 [TBL] [Abstract][Full Text] [Related]
12. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Catasus L; Gallardo A; Cuatrecasas M; Prat J Mod Pathol; 2009 Apr; 22(4):522-9. PubMed ID: 19234438 [TBL] [Abstract][Full Text] [Related]
13. Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma? Fadare O; Roma AA; Parkash V; Zheng W; Walavalkar V Adv Anat Pathol; 2018 Jan; 25(1):61-70. PubMed ID: 28945609 [TBL] [Abstract][Full Text] [Related]
14. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Alvarez T; Miller E; Duska L; Oliva E Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778 [TBL] [Abstract][Full Text] [Related]
16. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features. Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522 [TBL] [Abstract][Full Text] [Related]
18. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Alkushi A; Köbel M; Kalloger SE; Gilks CB Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148 [TBL] [Abstract][Full Text] [Related]
19. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034 [TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]